Low-grade glioma (LGG, WHO grade 2 — IDH-mutant) · None
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Track | aggressive |
|---|---|
| Linked regimen | None |
| ID | IND-RHABDOID-PREDISPOSITION-CARRIER-INTENSIFIED |
|---|---|
| Type | Indication |
| Status | reviewed 2026-05-19 | pending_clinical_signoff |
| Diseases | DIS-GLIOMA-LOW-GRADE |
| Sources | SRC-NCCN-CNS-2025 SRC-NCCN-GENETIC-FAMILIAL-BREAST-OVARIAN-2025 |
Notes
STUB pending two-Co-Lead signoff per CHARTER §6.1 dev-mode. Aggressive-observation alternative for RTPS1/RTPS2 confirmed carriers — shortest-feasible cadence + extended duration + SMARCA4 SCCOHT intensification + schwannomatosis tail. §15.2 C4 ≥2-tracks invariant: pairs with IND-RHABDOID-PREDISPOSITION-CARRIER-SURVEILLANCE.
Used By
No reverse references found in the YAML corpus.